• Clinical development

Publications

CYTOTHERAPY. August 2016, Volume 18, Issue 8, Pages 1043–1055. doi: 10.1016/j.jcyt.2016.05.010
Bjoern J, Iversen TZ, Nitschke JN, Andersen MH, Svane IM 
Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab
Elsevier Inc.

Clinical Cancer Research. January 2014. doi: 10.1158/1078-0432.CCR-13-1560
Iversen TZ , Engell-Noerregaard L, Ellebaek E, Andersen R, Stine Kiaer Larsen SK, Bjoern J, Zeyher C, Gouttefangeas C, Thomsen BM, Holm B, Straten PT, Mellemgaard A, Andersen MH, Svane IM
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase
AACR Publications

Oncoimmunology. 2016 Sep 30;5(11):e1238541. doi: 10.1080/2162402X.2016.1238541
Martinenaite E, Munir Ahmad S, Hansen M, Met Ö, Westergaard MW, Larsen SK, Klausen TW, Donia M, Svane IM, Andersen MH
CCL22 specific T Cells: Modulating the immunosuppressive tumor microenvironment
Taylor & Francis Online

Semin Immunopathol. 2016 Sep 27. [Epub ahead of print] Review. PMID: 27677755
Andersen MH
Anti-regulatory T cells 
PubMed.gov

Oncoimmunology. 2016 Jul 1;5(8):e1202391. doi: 10.1080/2162402X.2016.1202391
Munir Ahmad S, Martinenaite E, Hansen M, Junker N, Borch TH, Met Ö, Donia M, Svane IM, Andersen MH 
PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine
PubMed.gov

Cancer Immunol Immunother. 2016 Jan 2. [Epub ahead of print]
Ahmad SM, Borch TH, Hansen M, Andersen MH
PD-L1-specific T cells
PubMed.gov

Oncoimmunology. 2015 Aug 31;5(3):e1083672. eCollection 2016 Mar. article
Andersen MH
Novel understanding of self-reactive T cells
PubMed.gov

JNCI J Natl Cancer Inst (2015) Article
Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy
PubMed.gov

IDO

The immune system maintains a delicate balance between immunity and tolerance, protecting the host from pathogens while minimizing local tissue damage. The immunoregulatory enzyme Indolamine 2,3 dehydrogenase (IDO) is a critical endogenous cellular factor that contributes to immune suppression. IDO activity constitutes a counter regulatory mechanism induced by pro-inflammatory signals. This is also a crucial mechanism in cancer and cancer patients exhibit IDO elevation, which can be detected both in immune cells and on tumor cells. Thus, IDO is involved in the regulation of the immune response by suppressing T-cell function and enabling local tumor immune escape.

IDO is expressed in many different forms of cancer and hence treatment has the potential to be widely used.

It has already been verified that IDO-specific T-cells can be isolated from cancer patients and that these T-cells possess killing activity against tumor cells. Furthermore, these IDO specific T-cells can enhance other T-cell responses directly or indirectly.

Thus, IDO may serve as a widely applicable target for immunotherapeutic strategies.